Disproven
Laquinimod: slow disability worsening in relapsing MS
relapsing MS · T-cell co-stimulation / cytokine targeting
Placebo-controlled phase 3 trials missed their main goal, and none succeeded. This applies to this patient group only.
Laquinimod was refused in the EU. A positive trial result does not mean the medicine is available.
- Trials
- 1
- Running now
- 0
- Controlled phase 2/3 trials
- 1
- People in controlled trials
- 2199
Deciding trials (phase 3): 0 met, 1 did not.
Other linked trials: 0
Dose comparisons, trials against another medicine, add-on trials, phase 1 and uncontrolled studies. They are listed below but do not set the status.
Trials
Phase 3 · 2013 · Placebo-controlled · MSFT-NCT01707992
The deciding phase and counts come from the Trial Bank’s fixed rules.
Lab evidence
Lab studies in animals or cells. Results in animals often do not hold in people, and these studies never change the status of an idea.
Loading lab studies…
Loading reviews and guidelines…
History
- 2026-10-27First listed as Disproven
Related hypotheses
- Abatacept: reduce relapses and new lesions in relapsing MS
- Daclizumab: reduce relapses and new lesions in relapsing MS
- Dapirolizumab pegol: reduce relapses and new lesions in relapsing MS
- Frexalimab: reduce relapses and new lesions in relapsing MS
- Secukinumab: reduce relapses and new lesions in relapsing MS
- Ustekinumab: reduce relapses and new lesions in relapsing MS
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error